- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06260163
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR Jr)
April 23, 2024 updated by: Janssen Research & Development, LLC
A Phase 3 Randomized, Open-label Induction, Double-blind Maintenance, Parallel-group, Multicenter Protocol to Evaluate the Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
-
Gent, Belgium, 9000
- Recruiting
- UZ Gent
-
Jette, Belgium, 1090
- Recruiting
- UZ Brussel
-
-
-
-
-
Beijing, China, 100191
- Recruiting
- Peking University Third Hospital
-
Beijing, China, 100020
- Recruiting
- Capital Institute of Pediatrics
-
Changzhou City, China, 213004
- Recruiting
- Changzhou No 2 Peoples Hospital
-
Hangzhou, China, 310016
- Recruiting
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
-
Hangzhou, China, 310005
- Recruiting
- The Childrens Hospital Zhejiang University School Of Medicine
-
Shanghai, China, 200025
- Recruiting
- Ruijin Hospital, Shanghai Jiao Tong University
-
Shenyang, China, 110004
- Recruiting
- Shengjing Hospital of China Medical University
-
-
-
-
-
Hvidovre, Denmark, 2650
- Recruiting
- Hvidovre Hospital
-
-
-
-
-
Roma, Italy, 00161
- Recruiting
- AOU Policlinico Umberto I
-
-
-
-
-
Kanazawa, Japan, 920-8641
- Recruiting
- Kanazawa University Hospital
-
Kobe, Japan, 650-0017
- Recruiting
- Kobe University Hospital
-
Kumamoto, Japan, 861-8520
- Recruiting
- Japanese Red Cross Kumamoto Hospital
-
Matsumoto, Japan, 390-8621
- Recruiting
- Shinshu University Hospital
-
Saga, Japan, 849-8501
- Recruiting
- Saga University Hospital
-
Shinjuku, Japan, 160-0023
- Recruiting
- Tokyo Medical University Hospital
-
Takatsuki, Japan, 569-8686
- Recruiting
- Osaka Medical and Pharmaceutical University Hospital
-
Yokohama, Japan, 230-8765
- Recruiting
- Saiseikai Yokohamashi Tobu Hospital
-
-
-
-
-
Rzeszow, Poland, 35-302
- Recruiting
- Korczowski Bartosz Gabinet Lekarski
-
Warszawa, Poland, 04 501
- Recruiting
- Medical Network Spolka z o.o. WIP Warsaw IBD Point Profesor Kierkus
-
Warszawa, Poland, 04 730
- Recruiting
- Instytut Pomnik Centrum Zdrowia Dziecka
-
-
-
-
-
Ankara, Turkey, 06560
- Recruiting
- Gazi University Medical Faculty
-
-
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Riley Hospital for Children
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Weight greater than or equal to (>=) 10 kilogram (kg) at the time of consent for screening
- A pathology report to support a documented diagnosis of Ulcerative Colitis (UC) must be available in the source documents. There is no maximum duration for which a participant needs to be diagnosed with UC. If the pathology report to support a documented diagnosis of UC is not available in the source documents, the screening endoscopy with biopsies (obtained within 3 weeks before first study intervention administration) needs to support the diagnosis of UC.
- Moderately to severely active UC, defined by a baseline modified Mayo (without physician's global assessment) score of 5 through 9 inclusive, with a screening Mayo endoscopy subscore >= 2 as determined by a central review of the video of the endoscopy, and a baseline Mayo rectal bleeding subscore >=1
- Medically stable on the basis of physical examination, medical history, and vital signs, performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and acknowledged by the investigator
- Participants must have had an inadequate response and/or intolerance to biologic therapy and/or conventional therapies or be dependent upon corticosteroids
Exclusion Criteria:
- Have UC limited to the rectum only or to less than (<) 20 centimeter of the colon
- Presence of a stoma
- Has had any kind of bowel resection within 6 months or any other intra-abdominal surgery within 3 months of baseline
- Have severe colitis or have evidence of Crohn's Disease (CD)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open-label Induction Phase: Guselkumab Intravenously (IV)
Participants will receive a guselkumab dose IV based on their body weight (BW) during the 12-week open-label induction phase.
|
Guselkumab will be administered intravenously.
Other Names:
|
Experimental: Open-label Induction Phase: Guselkumab Subcutaneously (SC)
Participants will receive a guselkumab dose SC based on their BW during the 12-week open-label induction phase.
|
Guselkumab will be administered subcutaneously.
Other Names:
|
Experimental: Double-blind Maintenance Phase: Guselkumab SC or Guselkumab SC and Placebo SC
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive a guselkumab dose SC based on their BW or a guselkumab dose SC based on their BW and placebo SC up to Week 56.
|
Week 12 induction responders will be administered placebo (matching guselkumab up to Week 56) SC at protocol specified time points to maintain the blind.
Guselkumab will be administered subcutaneously.
Other Names:
|
Experimental: Open-label Maintenance Phase: Guselkumab SC
Week 12 non-responders will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 56.
|
Guselkumab will be administered subcutaneously.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Clinical Remission at Week 56
Time Frame: Week 56
|
Percentage of participants with clinical remission as assessed by modified Mayo score at Week 56 among participants who were induction responders will be reported.
Clinical remission per modified Mayo score is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.
|
Week 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Clinical Remission at Week 12
Time Frame: Week 12
|
Percentage of participants with clinical remission at Week 12 as assessed by modified Mayo score will be reported.
Clinical remission per modified Mayo score is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.
|
Week 12
|
Percentage of Participants With Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission at Week 12
Time Frame: Week 12
|
Percentage of participants with PUCAI remission at Week 12 will be reported.
It comprises 6 scales and ranges between 0 and 85 points.
The scales are abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal bowel movement, and activity level.
The PUCAI score is calculated as the sum of the 6 subscores.
A PUCAI score of less than (<) 10 indicates remission.
|
Week 12
|
Percentage of Participants with Symptomatic Remission at Week 12
Time Frame: Week 12
|
Percentage of participants with symptomatic remission at Week 12 will be reported.
Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.
|
Week 12
|
United States: Percentage of Participants with Endoscopic Improvement at Week 12
Time Frame: Week 12
|
Percentage of participants with endoscopic improvement as assessed by Mayo endoscopy subscore at Week 12 will be reported.
Endoscopic improvement is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.
|
Week 12
|
European Union: Percentage of Participants with Endoscopic Healing at Week 12
Time Frame: Week 12
|
Percentage of participants with endoscopic healing as assessed by Mayo endoscopy subscore at Week 12 will be reported.
Endoscopic healing is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.
|
Week 12
|
Percentage of Participants with Clinical Response at Week 12
Time Frame: Week 12
|
Percentage of participants with clinical response as assessed by modified Mayo score at Week 12 will be reported.
Modified Mayo score is a 3-component (stool frequency, rectal bleeding, and endoscopy subscores) assessment and does not include the physician's global assessment.
A decrease from baseline in the modified Mayo score by greater than or equal to (>=) 30 percent and >= 2 points, with either a decrease from baseline in the rectal bleeding subscore of >= 1 or a rectal bleeding subscore of 0 or 1.
|
Week 12
|
Percentage of Participants with Symptomatic Remission at Week 56
Time Frame: Week 56
|
Percentage of participants with symptomatic remission at Week 56 will be reported.
Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.
|
Week 56
|
United States: Percentage of Participants With Endoscopic Improvement at Week 56
Time Frame: Week 56
|
Percentage of participants with endoscopic improvement as assessed by Mayo endoscopy subscore at Week 56 will be reported.
Endoscopic improvement is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.
|
Week 56
|
European Union: Percentage of Participants With Endoscopic Healing at Week 56
Time Frame: Week 56
|
Percentage of participants with endoscopic healing as assessed by Mayo endoscopy subscore at Week 56 will be reported.
Endoscopic healing is defined as the Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.
|
Week 56
|
Percentage of Participants with Corticosteroid-free Clinical Remission at Week 56
Time Frame: Week 56
|
Percentage of participants with corticosteroid-free clinical remission at Week 56 will be reported.
Corticosteroid free clinical remission is defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline (Week 0), and not receiving corticosteroids for at least 8 weeks prior to Week 56
|
Week 56
|
Percentage of Participants with Clinical Response at Week 56
Time Frame: Week 56
|
Percentage of participants with clinical response as assessed by modified Mayo score at Week 56 will be reported.
Modified Mayo score is a 3-component (stool frequency, rectal bleeding, and endoscopy subscores) assessment and does not include the physician's global assessment.
A decrease from baseline in the modified Mayo score by >= 30 percent and >= 2 points, with either a decrease from baseline in the rectal bleeding subscore of >= 1 or a rectal bleeding subscore of 0 or 1.
|
Week 56
|
Percentage of Participants Histo-endoscopic Mucosal Improvement at Week 56
Time Frame: Week 56
|
Percentage of participants histo-endoscopic mucosal healing per endoscopy subscore and histologic improvement at Week 56 will be reported.
Histologic-endoscopic mucosal healing is defined as achieving a combination of histologic improvement and endoscopic improvement (US) or endoscopic healing (EU) (endoscopy subscore of 0 or 1).
|
Week 56
|
Percentage of Participants Who Achieve Endoscopic Normalization at Week 56
Time Frame: Week 56
|
Percentage of participants who achieve endoscopic normalization with an endoscopy subscore of 0 at Week 56 will be reported.
|
Week 56
|
Percentage of Participants With PUCAI Remission at Week 56
Time Frame: Week 56
|
Percentage of participants with PUCAI remission at Week 56 will be reported.
PUCAI comprises of 6 scales and ranges between 0 and 85 points.
The scales are: abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal bowel movement, and activity level.
The PUCAI score is calculated as the sum of the 6 subscores.
A PUCAI score of less than (<) 10 indicates remission.
|
Week 56
|
Serum Concentration of Guselkumab During Induction Phase
Time Frame: From Week 0 to Week 12
|
Serum samples will be analyzed to determine concentrations of guselkumab overtime.
|
From Week 0 to Week 12
|
Serum Concentration of Guselkumab During Maintenance Phase
Time Frame: From Week 12 to Week 56
|
Serum samples will be analyzed to determine concentrations of guselkumab over time.
|
From Week 12 to Week 56
|
Number of Participants with Incidence of Anti-guselkumab Antibodies
Time Frame: Up to Week 68
|
Number of participants with anti-guselkumab antibodies for all study treatment regimens will be assessed.
|
Up to Week 68
|
Percentage of Participants with Adverse Events (AEs)
Time Frame: Up to Week 68
|
Percentage of participants with AEs will be reported.
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
An AE does not necessarily have a causal relationship with the intervention.
|
Up to Week 68
|
Percentage of Participants with Serious Adverse Events (SAEs)
Time Frame: Up to Week 68
|
Percentage of participants with SAEs will be reported.
An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly.
|
Up to Week 68
|
Percentage of Participants with AEs Leading to Discontinuation of Study Intervention
Time Frame: Up to Week 68
|
Percentage of participants with AEs leading to discontinuation of study intervention will be reported.
|
Up to Week 68
|
Percentage of Participants with Symptomatic Remission at Week 56 Among Participants who had Symptomatic Remission at Week 12
Time Frame: Week 56
|
Percentage of participants with symptomatic remission at Week 56 among participants who had symptomatic remission at Week 12 will be reported.
Symptomatic remission score is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.
|
Week 56
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 19, 2024
Primary Completion (Estimated)
May 22, 2028
Study Completion (Estimated)
August 14, 2028
Study Registration Dates
First Submitted
February 7, 2024
First Submitted That Met QC Criteria
February 7, 2024
First Posted (Actual)
February 15, 2024
Study Record Updates
Last Update Posted (Actual)
April 24, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR109251
- 2022-001285-35 (EudraCT Number)
- CNTO1959PUC3001 (Other Identifier: Janssen Research & Development, LLC)
- 2022-502238-22-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colitis, Ulcerative
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
Clinical Trials on Matching Placebo
-
Syneos HealthShanghai Novamab Biopharmaceuticals Co. Ltd.Terminated
-
Huabo Biopharm Co., Ltd.Completed
-
GlaxoSmithKlineRecruitingEosinophilic Granulomatosis With PolyangiitisCanada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedAsthma; Allergic RhinitisChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
Anji PharmaCovanceCompletedFunctional ConstipationChina, United States
-
YSOPIA BioscienceCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Unknown
-
Immune DesignTerminatedSarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic SarcomaUnited States, Canada
-
Johnson & Johnson Pharmaceutical Research & Development...Completed